Quick results achieved with the Adtec SteriPlas
How often do LVAD patients with infection need treatment with the Adtec SteriPlas?
We recommend a minimum treatment of twice per week. This applies to both outpatients in day clinics and inpatients who have been admitted into the wards.
The treatment time itself is as quick as 3 minutes. During these short minutes, the components of cold plasma quickly bombard the cellular structure of bacteria to create micropores which allows access to the microbial DNA for total destruction. This applies to all forms of bacteria regardless of their resistance profile or if they are protected within biofilm.
How quick have patients with LVAD infections healed?
Our clinical evidence has shown patients have healed in as quick of two weeks of treatment. These are patients who have failed previous therapeutic attempts with conventional treatment methods.
Promising, consistent and reliable results achieved with the Adtec SteriPlas
Whilst Left ventricular assist devices (LVADs) have become essential mechanical pumps for patients who have had end stage heart failures, they are also prone to infections especially with the presence of biofilm that complicates treatment options. Cardiologists often rely on conventional antibiotic therapy but with rising antimicrobial resistance rates, they sometimes offer little to no help in achieving stabilisation.
The strong properties of the Adtec SteriPlas cold plasma has been proven to offer complete stabilisation of the LVAD system by destroying all forms of multi-resistant bacteria present, even if they are protected within biofilm. This is due to the unique cold plasma properties that can travel through the gaps around and down the driveline to reach the site of biofilm. This area would normally have been difficult to treat with conventional therapies such as antimicrobial dressings as they are hard to reach, but the Adtec SteriPlas has shown to travel to these sites with ease due to its remarkable antibacterial gaseous properties.
To learn more about our strong collection of clinical evidence, please contact us at info@adtecplasma.com to learn more
Safe UV and Reactive Species levels only with the Adtec SteriPlas
As a leading medical device company, the crucial balance of safety and clinical efficacy are a top priority. We are always conducting tests to demonstrate the approved safety and reliability of the Adtec SteriPlas but to also learn new ways to improve the use of cold plasma in medicine.
Our clinical studies already validate the safety of the Adtec SteriPlas, including its low-level UV and reactive species produced from the cold plasma. These two components are imperative for the physical destruction of bacteria, however, too much of a good thing can also be relatively damaging like that observed with cold plasma jet/pens and battery powered cold plasma devices.
Measured across multiple distances, the UV light produced is well below the ICNIRP limit of 30 J/m2 and the reactive species produced are well below the occupational limits set by NIOSH and UK HSE. The Adtec SteriPlas continues to be one of the only cold plasma medical devices that puts patient and user safety first with no reported side effects and promising clinical efficacy from every treatment conducted.
For more information about the Adtec SteriPlas, send us an email at info@adtecplasma.com
Casopis Lecba ran-page-003
Did you see the Adtec SteriPlas featured in the Czech Society for Wound Healing magazine?
Dr Hokynková from the Department of Burns and Plastic Surgery at Brno Hospital in Czech Republic had published a case study in the magazine to document the efficacy of the Adtec SteriPlas after having tested this on a variety of wounds including pressure ulcers and diabetic foot ulcers.
The article validates the SteriPlas’ ability to significantly reduce microbial load within the wound which allows the body to regain control and accelerate healing of stalled wounds. This includes wounds that are already contaminated with biofilm and listed for amputations. A change from the conventional therapies already existing on the market, the Adtec SteriPlas has proven to reverse further deterioration of complicated wounds and allow full healing and stability to be achieved.
For a translation of the article or to learn more about our efficacy and treatment options, please email us at info@adtecplasma.com
LVAD - Heidelberg publication 2021
Congratulations to Dr Kremer and the Cardiology Team at The University Hospital Heidelberg for their new publication, “Follow-Up after Cold Atmospheric Argon Plasma for Wound Management of Driveline Infections - A Promising Strategy”. This publication features the use of our Adtec SteriPlas medical device for the treatment of driveline infections (DLI). The results demonstrate how the safety, reliability and painless treatment from the Adtec SteriPlas can significantly reduce the wound and infection around the DLI, with the opportunity for sustainable freedom from DLI.
The SteriPlas sets foot in the U.S.A.
We are excited to share news of our collaboration with The Southern Illinois University in United States of America. Our Adtec SteriPlas will be used as part of their study to examine the effect of cold plasma on a variety of infection burn model cases in a research laboratory setting. This study aims to help tackle the outbreaks of antimicrobial resistant microorganisms that continues to be an issue for burns cases. We look forward to providing more information and the results as the study progresses.
Deep Sternum Surgical Site Infections (DSSIs)
Deep sternal surgical site infections (DSSIs) are a still a severe complication after cardiac surgery. The mortality estimated range is between 15%-40% of all cases. In addition to the significantly extended hospitalization, there is a significant cost burden with a calculated cost of € 36,000 for a single DSSI case.
The use of the Adtec SteriPlas for these complicated conditions has been actively documented as better managing the chronic infections, reducing hospitalization times and cost but more importantly it has shown to decrease the mortality rate. Our medical device has been praised as a tissue and life saving medical device.
Adtec SteriPlas for the treatment of deep sternal wound infections and infected drivelines
The Adtec SteriPlas has already been well documented for the treatment of deep sternal wound infections and infected drivelines. Separate studies from two leading hospitals in Germany (University Hospital Munster and University Hospital Heidelberg) have recorded the strong efficacy of our cold plasma treatment on these problematic conditions. Due to the original difficulty of managing these chronic infections using standard therapies along with the high rate of morbidity and mortality, it is no wonder why the Adtec SteriPlas has been chosen as the preferred treatment method.
You can read more about its story in the latest addition of the Chirurgische Allgemeine magazine: eSD_AdTecPlasma
SteriPlas cold plasma successful at killing multi-resistant bacteria
Our animation video shows how bacteria are easily destroyed using our patented cold plasma technology. The components of cold plasma work collectively to target bacteria and physically rupture the structure, allowing micropores to be created which gains access to the microbial DNA to be destroyed. This effectively kills bacteria, even if they are protected within biofilm.
Learn more about our clinical evidence by visiting our webpage www.adtechealthcare.com or send us an email at info@adtecplasma.com
Click the link below to access the animation video:
Animation video to show how the SteriPlas can successfully kill multi-resistant bacteria
Patient and user safety is priority with the Adtec SteriPlas
As a medical device company, we always strive to ensure the priority of patient and user safety. In comparison to battery-powered and smaller cold plasma devices which may produce unreliable and damaging levels of ozone and NOx, the Adtec SteriPlas has been carefully designed as a safe and well-balanced cold plasma medical device. It has been engineered to deliver predictable levels of cold plasma to ensure the continuity of no side effects reported, putting safety and efficacy at the top priority.
